Crizotinib nearly doubles progression-free survival in patients with ALK-positive lung cancer

被引：0
|
作者：
Mayor, Susan
机构：
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2012年 / 73卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：610 / 610
页数：1
相关论文
共 50 条
  • [31] Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance
    Xu, Haiyan
    Yang, Guangjian
    Yang, Lu
    Yang, Yaning
    Ma, Di
    Li, Junling
    Hao, Xuezhi
    Xing, Puyuan
    Wang, Yan
    THORACIC CANCER, 2019, 10 (05) : 1096 - 1102
  • [32] Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma
    Zito Marino, Federica
    Morabito, Alessandro
    Gridelli, Cesare
    Rocco, Gaetano
    Liguori, Giuseppina
    De Rosa, Nicla
    Botti, Gerardo
    Franco, Renato
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (09) : E86 - E88
  • [33] Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis
    Yang, Yan-Li
    Xiang, Zi-Jian
    Yang, Jing-Hua
    Wang, Wen-Jie
    Xiang, Ruo-Lan
    ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (04) : 1782 - 1796
  • [34] Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2016, 14 (06): : 241 - 243
  • [35] Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
    Gainor, Justin F.
    Sherman, Carol A.
    Willoughby, Kathryn
    Logan, Jennifer
    Kennedy, Elizabeth
    Brastianos, Priscilla K.
    Chi, Andrew S.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 232 - 236
  • [36] Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients
    Hongmei, L.
    Huang, M.
    Xu, Y.
    Zhou, X.
    Li, J.
    Wang, J.
    Peng, F.
    Gong, Y.
    Ding, Z.
    Zhu, J.
    Yu, P.
    Li, L.
    Hou, M.
    Ren, L.
    Wang, Y.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Combination of crizotinib and radiation in the treatment of ALK-positive and cetuximab-resistant lung cancer
    Li, Chunrong
    Huang, Shyhmin
    Walters, Noah
    Armstrong, Eric A.
    Harari, Paul M.
    CANCER RESEARCH, 2014, 74 (19)
  • [38] Ablative Local Therapy Extends The Clinical Benefit Of Crizotinib In Alk-positive Lung Cancer
    Gan, G. N.
    Camidge, D. R.
    Weickhardt, A. J.
    Doebele, R. C.
    Dzingle, W.
    Scheier, B.
    Kavanagh, B. D.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S211 - S211
  • [39] Ablative Local Therapy Extends the Clinical Benefit of Crizotinib in Alk-positive Lung Cancer
    Gan, G. N.
    Camidge, D. R.
    Weickhardt, A. J.
    Doebele, R. C.
    Dzingle, W.
    Scheier, B.
    Kavanagh, B. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S67 - S68
  • [40] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients.
    Yoshida, Tatsuya
    Oya, Yuko
    Shimizu, Junichi
    Tanaka, Kosuke
    Horio, Yoshitsugu
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345